pipeline – Talk Bio

JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus

3 days ago talkbio0Tagged Admilparant, Burning Mouth Syndrome, Camzyos, Cobenfy, Early-stage, JPM26, milvexian, pipeline, pumitamig

BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos

Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C

1 week ago talkbio0Tagged Antibody-Drug Conjugates, Cambridge office, Charles Fuchs, Chief Medical Officer, genentech, Hematology (discipline), NaPi2b, Neoplasms, pipeline, Roche (company), Series C financing, Solid Neoplasm, therapeutic autologous dendritic cells, TPBG gene, TUB-030, TUB-040, Tubulis

Charles Fuchs; Tubulis; Roche; Genentech; chief medical officer; antibody-drug conjugates; ADC pipeline; TUB-040; TUB-030; Series C financing; oncology; hematology; solid tumors; NaPi2b; 5T4; Cambridge office

Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program

2 months ago talkbio0Tagged Acquisition, BioNTech, Comirnaty, expansion, Metsera, mRNA Vaccine, Pancreatic carcinoma, Pfizer, pipeline

Pfizer; BioNTech; stake reduction; Candel Therapeutics; pancreatic cancer; Comirnaty; mRNA vaccine; Metsera acquisition; pipeline expansion

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

3 months ago talkbio0Tagged Drug Development, Generic competition, impairment charges, Late stage, Operating, pipeline, Q2 sales, restructuring, Takeda, Vyvanse

Takeda; pipeline cuts; generic competition; Q2 sales; Vyvanse; restructuring; operating profit; impairment charges; drug development; late-stage pipeline

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

3 months ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Novo throws weight behind budding rare disease pipeline

3 months ago talkbio0Tagged complement system, MASP-3 Inhibitor, Novo Nordisk, Omeros, Paroxysmal nocturnal hemoglobinuria, Payments, pipeline, Rare Diseases, Zaltenibart

Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the ‘Very Fair’ Deal and Plans to Polish a Rough Diamond

4 months ago talkbio0Tagged Acquisition, Antibodies, Bispecific, Breakthrough Therapy, Cancer of Neck, CEO, expansion, Genmab, Head, Merus, Neoplasms, Perspective, Petosemtamab, pipeline, United States Food and Drug Administration

Genmab; Merus; petosemtamab; acquisition; oncology; head and neck cancer; bispecific antibody; FDA Breakthrough Therapy; pipeline expansion; biotech; $8B deal; CEO perspective

VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery

4 months ago talkbio0Tagged Alzheimer 's disease, Antibodies, biobucks, brain-penetrant delivery, Capsid, Dependovirus, gene therapy, Huntington Disease, milestone payments, Neurodegenerative Disorders, pipeline, SHP-DB1, vectorized, VectorY

VectorY Therapeutics; Shape Therapeutics; SHP-DB1; adeno-associated virus (AAV) capsid; brain-penetrant delivery; gene therapy; neurodegenerative diseases; Huntington’s disease; Alzheimer’s disease; biobucks; pipeline; milestone payments; vectorized antibodies

Execution, Execution, Execution: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

5 months ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, Incretins, Leadership Change, Market, Maziar Mike Doustdar, Nordisk, Obesity, Ozempic, pipeline, Wegovy

Novo Nordisk; Maziar Mike Doustdar; obesity; diabetes; pipeline cuts; GLP-1 drugs; Wegovy; Ozempic; incretin market; leadership change

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

6 months ago talkbio0Tagged Business Development, Cell Therapy, Galapagos, Gilead Sciences, GLPG5101, Mantle cell lymphoma, pipeline, Sales - occupational activity, strategic alternatives

Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development